Last reviewed · How we verify
D064 and Placebo of D702, QD — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
D064 and Placebo of D702, QD (D064 and Placebo of D702, QD) — Chong Kun Dang Pharmaceutical. Unfortunately, no information is available on the mechanism of action of D064.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| D064 and Placebo of D702, QD TARGET | D064 and Placebo of D702, QD | Chong Kun Dang Pharmaceutical | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- D064 and Placebo of D702, QD CI watch — RSS
- D064 and Placebo of D702, QD CI watch — Atom
- D064 and Placebo of D702, QD CI watch — JSON
- D064 and Placebo of D702, QD alone — RSS
Cite this brief
Drug Landscape (2026). D064 and Placebo of D702, QD — Competitive Intelligence Brief. https://druglandscape.com/ci/d064-and-placebo-of-d702-qd. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab